Savient Pharmaceuticals, Inc. to Hold Fourth Quarter and Year-End 2012 Financial Results Conference Call on Tuesday, March 19, 2013
BRIDGEWATER, N.J., Feb. 26, 2013 /PRNewswire/ -- Savient Pharmaceuticals, Inc. (NASDAQ: SVNT) announced today that the Company's fourth quarter and year-end 2012 financial results will be released prior to the market open on Tuesday, March 19, 2013. Savient's executive management will host a conference call beginning at 9:00 a.m. Eastern Time on March 19, 2013, to discuss these results and to answer questions.
To participate by telephone, please dial 866-393-1565 (Domestic) or 253-237-1151 (International). The conference ID number is 99134844. The live and archived webcast can be accessed via the Investor Relations section of the Savient website at www.savient.com. A telephone replay will be available from 12:00 p.m. Eastern Time on March 19, 2013, through 11:59 p.m. Eastern Time on March 25, 2013, by dialing 855-859-2056 (Domestic) or 404-537-3406 (International) and entering conference ID number 99134844.
ABOUT SAVIENT PHARMACEUTICALS, INC.
Savient Pharmaceuticals, Inc. is a specialty biopharmaceutical company focused on developing and commercializing KRYSTEXXA® (pegloticase) for the treatment of chronic gout in adult patients who do not respond to conventional therapy. Savient has exclusively licensed worldwide rights to the technology related to KRYSTEXXA and its uses from Duke University ("Duke") and Mountain View Pharmaceuticals, Inc. ("MVP"). Duke developed the recombinant uricase enzyme and MVP developed the PEGylation technology used in the manufacture of KRYSTEXXA. MVP and Duke have been granted U.S. and foreign patents disclosing and claiming the licensed technology and, in addition, Savient owns or co-owns U.S. and foreign patents and patent applications, which collectively form a broad portfolio of patents covering the composition, manufacture and methods of use and administration of KRYSTEXXA. In the U.S., Savient also supplies Oxandrin® (oxandrolone tablets, USP) CIII and co-promotes Kineret® (anakinra) with Swedish Orphan Biovitrum AB (Sobi). For more information, please visit the Company's website at www.savient.com.
SVNT-I
CONTACT: | |
Savient Pharmaceuticals, Inc. | Burns McClellan |
John P. Hamill | Caitlyn Murphy |
Senior Vice President and Chief Financial Officer | |
(212) 213-0006 | |
(732) 418-9300 |
SOURCE Savient Pharmaceuticals, Inc.